Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) was the target of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,170,000 shares, a decrease of 17.6% from the December 31st total of 1,420,000 shares. Based on an average daily trading volume, of 4,600,000 shares, the short-interest ratio is presently 0.3 days. Approximately 3.3% of the shares of the company are short sold.
Athira Pharma Price Performance
Shares of ATHA stock traded down $0.01 during trading hours on Friday, reaching $0.53. 184,809 shares of the company were exchanged, compared to its average volume of 209,871. The stock’s fifty day moving average is $0.58 and its two-hundred day moving average is $1.23. Athira Pharma has a fifty-two week low of $0.41 and a fifty-two week high of $4.30. The company has a market cap of $20.31 million, a price-to-earnings ratio of -0.18 and a beta of 2.99.
Athira Pharma (NASDAQ:ATHA – Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.05. On average, research analysts anticipate that Athira Pharma will post -2.35 earnings per share for the current year.
Hedge Funds Weigh In On Athira Pharma
About Athira Pharma
Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.
Featured Articles
- Five stocks we like better than Athira Pharma
- What Investors Need to Know About Upcoming IPOs
- Nebius Group: Market Overreaction or Real AI Disruption?
- 3 Monster Growth Stocks to Buy Now
- The Best Way to Invest in Gold Is…
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Why Nike Stock Could Be 2025’s Top Comeback Play
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.